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ORIGINAL ARTICLE
Clinical Value of Fluorodeoxyglucose-Positron Emission
Tomography/Computed Tomography in Differentiation of
Malignant Mesothelioma from Asbestos-Related Benign
Pleural Disease
An Observational Pilot Study
Huseyin Yildirim, MD,* Muzaffer Metintas, MD,* Emre Entok, MD,† Guntulu Ak, MD,*
Ilknur Ak, MD,† Emine Dundar, MD,‡ and Sinan Erginel, MD*
Background: Several studies have already addressed the potential
role of an increased fluorine 18 fluorodeoxyglucose (18F FDG)
uptake in identification of pleural malignancy. In this pilot study, we
investigate the role of 18F-FDG positron emission tomography/
computed tomography (PET/CT) for differentiating asbestos-related
benign pleural disease from malignant mesothelioma.
Materials and Methods: The study population comprised 31 con-
secutive patients (17 malignant mesotheliomas, nine benign asbestos
pleurisies, and five diffuse pleural fibrosis) with a mean age of 61
years between January 2006 and December 2008. Thoracoscopy or
image-guided pleural needle biopsy were systematically performed
to reveal pathologic diagnosis and/or clinical follow-up for at least
3 years for presence or absence of malignant pleural effusion. ROCs
analyses for standardized uptake value (SUV) adjusted to body
weight were calculated between benign and malignant pleural
diseases.
Results: 18F-FDG PET/CT imaging correctly detected the presence
of malignancies in 15 of 17 patients with malignant mesothelioma
for sensitivity, specificity, and overall accuracy of 88.2%, 92.9%,
and 90.3%, respectively. 18F-FDG PET/CT imaging correctly iden-
tified 13 of 14 cases of benign pleural disease. The mean SUV
values were 6.5  3.4 for malignant mesothelioma cases and 0.8 
0.6 for benign pleural diseases (p  0.001). When we compared the
two groups of pleural disease, a cut-off value of 2.2 for SUV gave
the best accuracy with 94.1%, 100%, 100%, and 93.3% for sensi-
tivity, specificity, positive predictive value, and negative predictive
value, respectively.
Conclusion: Preliminary results of this trial provide evidence that
18F-FDG PET/CT imaging is a highly accurate and reliable nonin-
vasive test to decide for further investigation of differentiating
malignant mesothelioma from benign pleural disease.
Key Words: 18F-fluorodeoxyglucose positron emission tomogra-
phy-computed tomography, Asbestos, Pleural disease, Malignant
mesothelioma, Diffuse pleural thickening, Benign asbestos-related
pleural effusions.
(J Thorac Oncol. 2009;4: 1480–1484)
Asbestos-related lung diseases have emerged as a majorworldwide public health problem. Asbestos is a mineral
that has been extensively mined and used for a large number
of purposes all over the world. Exposure to asbestos, either
occupational or environmental, is strongly correlated with the
development of malignant pleural mesothelioma (MPM).
Apart from malignant diseases, it is also well known that
asbestos can cause benign lesions of the pleura, including
pleural plaques, benign asbestos-related pleural effusion
(BAPE), and diffuse pleural thickening (DPT).1 The median
survival after the diagnosis of pleural mesothelioma is be-
tween 9 and 12 months.2 The management of patients with
MPM is controversial. Multimodality regimens combining
chemotherapy, radiotherapy, immunotherapy, and surgery are
being used more frequently in patient management.3 It is well
known that the best chance for long-term survival is achieved
with early diagnosis and aggressive surgery. For this reason,
early discrimination between MPM and benign pleural dis-
ease is important for treatment and prognosis.4
Imaging plays a pivotal role in the diagnosis and
subsequent management of patients with pleural disease. A
plain chest radiography is usually the first imaging for me-
sothelioma. Today, computed tomography (CT) and magnetic
resonance imaging have been widely used as the primary
imaging modality for the diagnosis, staging, and monitoring
of therapeutic response in mesothelioma.5 The positron emis-
sion tomography (PET)/CT system has become widespread
and plays an important role in clinical oncology. The clinical
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utility of fluorine 18 fluorodeoxyglucose (18F-FDG) PET/CT
in evaluating pleural malignancies has not been well defined.
Although these imaging techniques can be valuable in
assessing the possibility of the MPM, certain diagnosis is still
most often established through pleural fluid examination or
tissue biopsy. However, cytologic examination of pleural
fluid and closed pleural biopsy is relatively insensitive to
reach the diagnosis. In a previous study from our group, we
have shown that the diagnosis of MPM was made with
CT-guided pleural needle biopsy in 83.3% of cases.6 On the
other hand, tissue samples can be obtained through thoracos-
copy with a diagnostic sensitivity of more than 90%, but it is
an invasive procedure and cannot be used for patients with
progressive disease or advanced in age.
The aim of this study was to report our clinical expe-
rience with 18F-FDG PET/CT for differentiating between
MPM and asbestos-related benign pleural disease.
PATIENTS AND METHODS
Patients
An observational pilot study was performed in patients
with pleural disease consecutively admitted to our hospital
from January 2006 to December 2008. The study population
consisted of 31 patients with pleural effusions or pleural
thickening who were recruited from the Department of Chest
Disease, Eskisehir Osmangazi University, Turkey. According
to their final diagnosis, the patients were subdivided into
three groups: patients with MPM (n 17), patients with DPT
(n 5), and patients with BAPE (n 9). A benign group was
identified through a chart review of patients who had been
followed at our hospital, and these patients were invited to
perform FDG-PET study. The patients with DPT or BAPE
were followed in 6 months intervals for the first 3 years and
then annually by CT. Physical examination, chest radiogra-
phy, and 18F-FDG PET/CT scans were obtained in all patients
who gave informed consent. Exclusion criteria were any
concomitant infectious disease, previous therapy against
MPM, or patients with metastatic pleural disease.
To be included into the analyzed group, patients were
classified into different diagnostic groups based on the fol-
lowing explicit criteria:
1. DPT defined on the basis of chest radiograph or CT scan
results. On a plain chest radiography, DPT is characterized
by bilateral thickening involving at least 25% of the chest
or 50% if unilateral, pleural thickening greater than 5 mm
at any site, and obliteration of the costophrenic angle. On
CT, DPT is defined as continuous sheet of thickening at
least 5 cm in lateral extent 8 to 10 cm in craniocaudal
extent and with a 3-mm thickness.5 All patients with DPT
had been followed for 3 years.
2. BAPE: Diagnostic criteria of BAPE include history of
direct or indirect exposure to asbestos, exclusion of
other causes of effusion by thoracoscopy or diagnostic
thoracotomy, particularly tuberculosis and malignancy,
and no malignancy detected within 3 years after the
onset of the effusion.7
3. MPM cases were diagnosed histopathologically.
FDG-PET Imaging
18F-FDG PET/CT imaging was performed at baseline
within the 2 weeks before invasive procedure. All patients
fasted for at least 6 hours before PET/CT examination, and
their blood glucose concentrations were measured by finger
stick. The injected dose of 18F-FDG (Monrol, Kocaeli, Tur-
key) varied between 350 and 450 MBq depending on the
patient’s weight. Image acquisition was performed using an
integrated PET/CT device (Biograph 6 Hirez PET/CT, Sie-
mens, Knoxville, TN). CT was performed from the head to
the pelvic floor using a standardized protocol (120 KV, 80
mA with a slice thickness of 5 mm). PET images were
acquired using 3D mode for the same scanning range as CT.
The acquisition time for PET was 3 minutes per bed position,
and 5 to 6 continuous positions were scanned. PET images
datasets were reconstructed iteratively using an ordered sub-
set expectation maximization algorithm and corrected with
measured attenuation correction. The images were assessed
visually on axial, coronary, and sagittal reconstruction. All
areas with abnormally increased 18F-FDG uptake correspond-
ing to a CT abnormality were interpreted as positive for
malignancies. Suggestive findings on CT were interpreted as
negative if they did not correspond to an area of abnormally
increased 18F-FDG uptake. For a semiquantitative analysis of
metabolic activity, a regions of interest (ROIs) analysis was
performed. The ROIs were drawn manually around areas of
the lesions. The ROIs data were used to calculate standard-
ized uptake values (SUVs) on the 18F-FDG PET/CT images.
The SUV was determined according to the standard formula,
with activity in the ROIs given in Bq/ml per injected dose in
Bq/weight.
Outcomes were assessed by nuclear physician who
were aware of patients histopathological diagnosis and clin-
ical status.
Histopathology
Each of the biopsy specimens obtained by invasive
procedures such as CT-guided pleural biopsy, thoracoscopy,
or diagnostic thoracotomy were reviewed by trained single
pathologists in our institute, and all mesothelioma cases were
diagnosed using the currently accepted histologic criteria
combined with the immunohistochemical features. A panel of
antibodies (cytokeratin cocktail, calretinin, epithelial mem-
brane antigen, carcinoembryonic antigen and Ber EP4, and
WT1) was applied for distinguishing mesothelioma from
metastatic carcinoma.
Statistical Analysis
All statistical tests were performed out using SPSS
(version 10.0; SPSS Inc., Chicago, IL). The 2 test was used
to evaluate the association between categorized variables.
The Mann-Whitney U test was used to compare SUVmax of
malignant mesothelioma with those of benign pleural disease.
A receiver operating characteristic (ROC) curve were gener-
ated using commercial software, and the optimal cut-off point
was determined for SUVmax. All tests were considered
significant at p  0.05.
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RESULTS
A total of 40 patients were enrolled in the study. Nine
patients were excluded from the analysis because of meta-
static pleural disease (n  5), tuberculous pleural effusions
(n 3), and incomplete follow-up (n 1). The patient cohort
consisted of 31 patients (20 men and 11 women), with a mean
age of 61 years (range, 40–82 years). MPM was diagnosed in
17 patients, DPT in five patients, and BAPE in nine patients.
From the 17 patients with MPM, 11 (64.7%) were of epithe-
lioid mesothelioma, three (17.6%) were biphasic mesotheli-
omas, two (11.8%) were sarcomatoid mesothelioma, and one
(5.9%) was undetermined subtype. There was a significant
difference in the mean exposure duration between malignant
and benign groups (30.9 years versus 12.3 years, respec-
tively; p  0.05).
In the malignant group, six patients were diagnosed by
open pleural biopsy at thoracotomy, and 11 patients were
diagnosed by a transpleural method: closed pleural needle
biopsy (n  5), medical thoracoscopy (n  3), and transtho-
racic needle biopsy (n  3). By contrast, in the benign group,
diagnosis were obtained by closed pleural needle biopsy in
three patients, medical thoracoscopy in four patients, and
open pleural biopsy at thoracotomy in one patient. Of this
latter group, the remaining six patients underwent at least 3
years of clinical follow-up documenting no clinical or radio-
logic progression of their disease.
Overall, 18F-FDG PET/CT imaging correctly detected
15 of 17 cases of MPM by the reports of the Department of
Nuclear Medicine (Figure 1). Two patients were not correctly
identified by metabolic imaging with an absence of FDG uptake.
One patient had a histologically confirmed epithelial subtype,
and one had a sarcomatoid subtype. 18F-FDG PET/CT imaging
correctly detected 13 of 14 benign lesions. Furthermore,
18F-FDG PET/CT scan results were falsely interpreted as posi-
tive in a patient with histologic diagnosis of DPT. In all
patients with BAPE, 18F-FDG PET/CT imaging revealed an
absence of FDG uptake within the pleura. A patient with a
false-positive PET result was still alive at a median follow-up
FIGURE 1. In patients with malignant me-
sothelioma, transverse FDG imaging re-
vealed extensive pleural involvement of the
right pleura with a maximal standardized
uptake value of 6.25 (A, top). In a case of a
benign pleural lesion, PET imaging revealed
an absence of FDG uptake within the
pleura, and this image suggests the benign
nature of this lesion (B, bottom).
FIGURE 2. Receiver operating characteristic (ROC) curve
for standardized uptake value (SUV). The area under the
ROC curve for SUVmax was 0.983.
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25 months with no signs or symptoms of malignancies. For
the above results, the sensitivity of 18F-FDG PET/CT imag-
ing to detect pleural mesothelioma was 88.2%, the specificity
was 92.9%, and overall accuracy was 90.3%.
The uptake of FDG was significantly higher in patients
with mesothelioma than in benign lesions. The mean SUVmax
in MPM was 6.5  3.4, whereas the mean SUVmax in benign
pleural disease was 0.8  0.6, and the differences were statis-
tically significant (p  0.001). In the ROC analysis, we calcu-
lated SUV of more than 2.2 for SUV as having the highest
diagnostic accuracy (Figure 2). In one patient who was diag-
nosed malignant mesothelioma, the obtained SUVmax value
was below the calculated cut-off level (SUVmax  1.49). We
calculated that the sensitivity, specificity, positive predictive
value, and negative predictive value of this value were 94.1%,
100%, 100%, and 93.3%, respectively.
DISCUSSION
The differentiation between malignant mesothelioma
and asbestosis-related benign pleural disease poses a diag-
nostic challenge to the physician. Our study suggests that
18F-FDG PET/CT is an effective tool that differentiates
malignant from benign pleural disease with sensitivity of
88.2% and specificity of 92.9% according to the expert
reports from the Department of Nuclear Medicine. Thus,
18F-FDG PET/CT was useful for the characterization of
asbestosis-related benign pleural disease, helping avoid un-
necessary invasive procedures.
We found that 18F-FDG PET/CT facilitated the detec-
tion of the tumor in 88.2% of cases. In 15 of 17 patients, there
was FDG avidity representing MPM. In two of our malignant
cases, no abnormal pleural uptake was seen on the 18F-FDG
PET/CT imaging; this might be explained by tumor charac-
teristics. According to the literature, tumors with low meta-
bolic activity such as bronchioloalveolar carcinoma and car-
cinoid tumors can give rise to false-negative results.8 In
addition, false-negative malign mesothelioma cases were also
reported in literature.9 We observed that 18F-FDG PET/CT
imaging was false positive in one patient. False-positive FDG-
PET results have been reported in patients with pneumonia,
sarcoidosis, pleural fibrosis, round ateletasis, talc pleurodesis,
and caseating granulomas. Infectious and inflammatory lesions
may have increased 18F-FDG accumulation and mimic tumor. In
most cases, these findings are attributed to the increased meta-
bolic state of accumulated inflammatory cells.10
Our results show that the ROC curve for SUVmax had
the highest accuracy at differentiating malignant mesotheli-
oma from benign lesion. With a SUVmax threshold of 2.2,
sensitivity, specificity, positive predictive value, and negative
predictive value for detecting malignant mesothelioma were
94.1%, 100%, 100%, and 93.3%, respectively. We show that
a SUVmax values greater than 2.2 is always associated with
malignancies and require biopsy. On the other hand, we did
not detect any benign lesions above SUVmax of 2.2. The high
negative predictive value of 18F-FDG PET in our study indicates
that lesions with a SUVmax values less than 2.2 are probably
benign and usually do not need further invasive diagnostic
work-up. However, it should be noted that the predictive values
of a test depend on the prevalence of the abnormality in the
patients being tested. Therefore, we believe that close follow-up
is necessary in most of these patients.
The diagnosis of MPM requires immunohistopatho-
logical analysis of tissue samples, which were obtained from
pleural lesions by invasive procedures such as CT-guided
pleural biopsy, thoracoscopy, or thoracotomy. However, non-
invasive diagnostic methods may be important for patients in
bad state or patients who do not want any invasive biopsy
procedures. It is also possible to identify cases with a low
probability of MPM, possibly related with negative predictive
value, which could be calculated with ROC analysis. To
improve the diagnosis of MPM, a number of serum or pleural
fluid markers have been intensively evaluated, but the re-
search for an acceptable marker has so far been insufficient.
Recent reports have raised interest on soluble mesothelin-
related peptides, megakaryocyte potentiating factor, and os-
teopontin as possible markers for diagnosing MPM.11 An
important question is that whether these markers may be used
to screen individuals having occupational or environmental
risk factors.
Accordingly, recent advances have increased the im-
portance of imaging modalities. Our study group previously
reported that the CT findings of “rind-like pleural involve-
ment,” “mediastinal pleural involvement,” “pleural nodular-
ity,” and “pleural thickness more than 1 cm” were indepen-
dent findings for differentiation of malignant pleural diseases
from benign pleural disease with the sensitivity/specificity
values of 54/95%, 70/83%, 38/96%, and 47/64%, respec-
tively.12 Magnetic resonance imaging is superior to CT in the
assessment of chest wall and diaphragmatic involvement of
mesothelioma.13 As the most recent nuclear medicine imag-
ing modality, PET imaging with 18F-FDG has been widely
used in thoracic oncology primarily to distinguish between
benign and malignant disorders, including lung cancer.
Several studies have already addressed the potential
role of an increased 18F-FDG uptake in identification of
pleural malignancy. The sensitivity of 18F-FDG PET/CT in
our patient group is similar to previously reported sensitivi-
ties. Benard et al.14 reported that FDG-PET is a sensitive
imaging method for differentiating malignant from benign
involvement in patients with asbestos exposure who present
with pleural effusions or pleural thickening on CT scanning.
Also, they concluded that using an SUV of greater than 2.0 to
differentiate benign from malignant disease, the sensitivity,
specificity, and overall accuracy of the method were 91%,
100%, and 92%, respectively. In a prospective study, Kramer
et al.9 studied 32 patients and concluded that qualitative
assessment of pleural thickening with PET accurately dis-
criminates between malignant and benign pleural thickening,
with a high accuracy and negative predictive value. They also
suggested that patients with pleural thickening and negative
PET findings may be followed up using only CT instead of
pathologic diagnostic procedures. Similarly, Qureshi and
Gleeson5 reported that patients with pleural thickening and a
negative PET scan do not routinely require histologic verifi-
cation but do require radiologic follow-up. A study by Car-
retta et al.15 suggested that 18F-FDG PET may have a great
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potential, both in the differential diagnosis of pleural diseases
and in the evaluation of the response to treatment.
Possible application of 18F-FDG PET/CT for imaging of
mesothelioma are to detect and stage the extent, to differentiate
between malignant and benign lesion in patient with asbestos
exposure, assessment of disease progression, and evaluation of
disease response to treatment.4 18F-FDG PET/CT increases the
accuracy of overall staging in patients with MPM and signifi-
cantly improves the selection of patients for curative surgical
resection.16 Specifically, 18F-FDG PET/CT detects more exten-
sive disease involvement than that shown by other imaging
modalities and is particularly useful in identifying occult distant
metastases.17 18F-FDG PET/CT is a noninvasive imaging tech-
nique, which has recently been validated for the assessment of
therapy response in patients with malignant mesothelioma.18
18F-FDG PET/CT also can predict the prognosis of MPM.19 In
our study, we observed that 18F-FDG PET/CT can be useful to
decide further investigations for the patients who had asbestos-
related pleural diseases.
In our study, our sample size was relatively small. This
is the limitation of our study. On the other hand, although
18F-FDG–PET/CT has proven to be the best noninvasive
imaging tool for differentiation of malignant disease, it is a
relatively expensive imaging technique yet.
In conclusion, the early discrimination of clinically
aggressive malignant mesothelioma would be clinically use-
ful. The preliminary findings of this pilot study suggest that
adding 18F-FDG PET/CT imaging to the diagnostic workup
of patients with malignant mesothelioma may limit the num-
ber of unnecessary invasive procedures or may be useful to
decide the indication of invasive methods for cases with high
suspicious of MPM. Accordingly, 18F-FDG PET/CT should
be considered as noninvasive diagnostic test for distinguish-
ing of malignant pleural disease from benign lesion.
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